- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic lymphocytic leukaemia (CLL); small lymphocytic lymphoma (SLL)
- Meeting Date: November 2019
- Public Summary Document (PSD) November 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) November 2019 PBAC Meeting - (Word 181KB)
Ibrutinib – November 2019
Ibrutinib: Capsule 140 mg; Imbruvica®
Last updated
6 March 2020